Companies: 10,795·Total market cap: $144.5T
Celularity Inc.

Celularity Inc.

CELUNASDAQHealthcare● Active
$0.81
$-0.06(-6.92%)
Market Cap$19528914
P/E Ratio
52W High$4.35
52W Low$0.71
Overview

Celularity Inc. (CELU) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

celu · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Celularity Inc. (CELU) measures how much investors pay for each dollar of the company's trailing earnings. CELU's current PE ratio of N/A is calculated by dividing its stock price of $0.81 by its TTM earnings per share of -$3.58.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E
N/A
FY2026 est. EPS $-2.75
Based on 1 analyst
EPS (TTM)
-$3.58
TTM · diluted EPS
PEG Ratio
0.01
Below 1.0 · Growth adjusted
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Celularity Inc. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-09

PE Ratio History

2018 – 2025 · Annual
PE Ratio (TTM)
5Y Avg 12.7x
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
Celularity Inc.
Celularity Inc.You
CELU
$20MN/A-$3.58
Annovis Bio, Inc.
Annovis Bio, Inc.
ANVS
$35MN/A-$1.40
Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc.
ATNM
$33MN/A-$1.09
BioAtla, Inc.
BioAtla, Inc.
BCAB
$4MN/A-$50.66
BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc.
BTAI
$34MN/A-$5.73
FibroGen, Inc.
FibroGen, Inc.
FGEN
$37M0.19x$45.38
Generation Bio Co.
Generation Bio Co.
GBIO
$36MN/A-$19.76

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 8 of 8 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-12-31Latest
FY2025
$-3.59
2024-12-31
FY2024
$-2.64
2023-12-31
FY2023
$-11.02
2022-12-31
FY2022
12.72x$1.01
2021-12-31
FY2021
$-7.87
2020-12-31
FY2020
$-113.06
2019-12-31
FY2019
$-88.75
2018-12-31
FY2018
$-0.00

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for Celularity Inc. (CELU) measures how much investors pay for each dollar of the company's trailing earnings. CELU's current PE ratio of N/A is calculated by dividing its stock price of $0.81 by its TTM earnings per share of -$3.58.

PE Ratio = Stock Price ÷ EPS (TTM)
= $0.81 ÷ -$3.58 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

CELU pe ratio · 6 questions

CELU's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.81 and TTM EPS of -$3.58. Data sourced from Financial Modeling Prep via CELU's SEC 10-K and 10-Q filings.

CELU PE ratioWhat is CELU PE ratioCurrent PE ratio of CELUCELU PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Celularity Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09